Investor Presentation
•
Commercialisation Strategy
TGA Approval for XV LVAS
received September 2020
4DMedical's XV LVAS approved by the TGA for
inclusion in Australian Register of Therapeutics
Goods (ARTG)
• TGA approval was received 6 months ahead of
schedule
●
4DMedical intends to clearly define a path for
immediate adoption of its SaaS product and supply
of the software across Australia, with a sales and
marketing team being established to deliver
Australian customers in 2021
• 4DMedical is now well positioned to progress the
global rollout of XV LVAS having also received FDA
510(k) clearance in May 2020
Investments made in 4DMedical's core US market
will have positive flow on effects in Australia
"4DMedical lung imaging technology provides a
rare and exciting opportunity to improve lung
health outcomes for patients globally"
Professor Greg Snell
Head of Lung Transplant Service, Alfred Hospital
Australian Market
Opportunity
A$400m Total Spend
5.3m Procedures Annually
Pg 29 | Investor presentation
4DMedicalView entire presentation